Since CD8+ T cells are hypothesized to be the final effector cells that mediate tumor cell killing, changes in intratumoral CD8+ T cell dynamics serve as a pharmacodynamic marker of clinical activity in certain indications. Here, CD8A is linked to neoplasm.